title: [Surgical session: neovascular glaucoma and anti-vascular endothelial growth factor treatment].
abstract: Recent research has shown the key role of vascular endothelial growth factor (VEGF), mainly one of its isoform, VEGF-A, in ocular pathologies involving neovascularization. New intraocular treatments targeting specifically VEGF (anti-VEGF) has been developed. These agents have revolutionized the treatment and visual prognosis of neovascular agerelated macular degeneration (AMD). Their potential for other ocular diseases, such as neovascular glaucoma, is currently under clinical investigations. We briefly review the current knowledge and clinical data, and present our clinical experience with the use of intravitreal bevacizumab in neovascular glaucoma.
authors.affiliation: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, 28, rue de Charenton, F-75571 Paris cedex 12, France. olaplace@numericable.fr
authors.forename: O
authors.initials: O
authors.lastname: Laplace
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab